GURVE Grupo de Radioterapia Oncológica, Caracas, Venezuela.
Am J Clin Oncol. 2011 Feb;34(1):32-7. doi: 10.1097/COC.0b013e3181cae8ab.
Primary carcinomas of the trachea are rare tumors, occurring at a rate of 2.6 new cases per 1,000,000 people per year. This study investigates the large observational cohort of patients recorded in the NCI Surveillance, Epidemiology, and End Results (SEER) 1973-2004 database, and provides information regarding epidemiology, treatment, and prognosis.
The SEER database was investigated, and all patients for whom primary tracheal carcinoma was the first and only cancer were investigated. Demographic information was investigated. The cohort was analyzed for variables effecting survival, including age, gender, race, histology, extent of disease, extent of surgery, use of radiation, and year of diagnosis.
Between 1973 and 2004, 578 cases of primary tracheal carcinomas were reported in the SEER database. There were 322 men (55.7%) and 256 women (44.3%). Squamous cell carcinoma was the predominant histology, representing 259 tumors (44.8%). Adenoid cystic carcinoma (ACC) was the second most common tumor (16.3%). Localized, regional and distant disease was found in 140 (24.2%), 212 (36.7%), and 108 (18.7%), respectively. Twenty percent of the patients did not undergo staging. Patients with localized disease had a better prognosis than those with regional (P = 0.001) or distant disease (P = <0.001).A significant fraction of patients did not receive cancer directed local therapy; 34.3% did not undergo surgery and 29.1% did not receive any kind of radiation therapy. There was a statistically significant improved survival for patients who underwent any type of surgery in comparison with patients who did not undergo cancer directed surgery. There was no statistical benefit for patients who underwent radiation therapy.General overall 5-year survival for all patients was 27.1% (95% CI: 23.1-33.3%). Patients with localized disease had a better outcome than patients with regional or distant disease with an overall 5-year survival of 46% (95% CI: 37.3%-55.8%). Squamous cell carcinoma tumors had worse outcomes than any other histologic type, with a 5 year overall survival of 12.6% (95% CI: 8.4-17.6%). In contrast, 5-year overall survival for AACs was relatively good at 74.3% (95% CI: 63.1-82.5). For localized disease, 5-year survival was 24.7% (95% CI: 12.8-38.7%) for squamous cell carcinoma versus 90.5% (95% CI: 73.3-96.8%) for ACCs (P < 0.001).
Primary tracheal tumors are very uncommon; squamous cell carcinoma is the most common histologic type, followed by ACCs. General 5-year overall survival is poor, though localized disease has better survival when compared with regional or distant disease. There is a remarkable difference in survival between squamous cell carcinoma and ACC.
原发性气管癌是一种罕见的肿瘤,每年每 100 万人中有 2.6 例新发病例。本研究调查了 NCI 监测、流行病学和结果(SEER)1973-2004 数据库中记录的大量观察性患者队列,并提供了有关流行病学、治疗和预后的信息。
调查了 SEER 数据库,并对所有原发性气管癌为首发且唯一癌症的患者进行了调查。调查了人口统计学信息。对影响生存的变量进行了分析,包括年龄、性别、种族、组织学、疾病程度、手术范围、放疗使用和诊断年份。
1973 年至 2004 年间,SEER 数据库报告了 578 例原发性气管癌病例。其中 322 名男性(55.7%)和 256 名女性(44.3%)。鳞状细胞癌是最常见的组织学类型,占 259 例(44.8%)。腺样囊性癌(ACC)是第二常见的肿瘤(16.3%)。局部、区域和远处疾病分别发现 140 例(24.2%)、212 例(36.7%)和 108 例(18.7%)。20%的患者未进行分期。局部疾病患者的预后优于局部(P=0.001)或远处疾病(P<0.001)患者。相当一部分患者未接受癌症定向局部治疗;34.3%未接受手术,29.1%未接受任何类型的放疗。与未接受癌症定向手术的患者相比,接受任何类型手术的患者生存时间明显延长。接受放疗的患者没有统计学上的获益。所有患者的总体 5 年生存率为 27.1%(95%CI:23.1%-33.3%)。局部疾病患者的预后优于局部或远处疾病患者,总体 5 年生存率为 46%(95%CI:37.3%-55.8%)。与其他任何组织学类型相比,鳞状细胞癌肿瘤的预后更差,5 年总生存率为 12.6%(95%CI:8.4%-17.6%)。相比之下,5 年总生存率对于 AAC 为相对较好,为 74.3%(95%CI:63.1%-82.5%)。对于局部疾病,鳞状细胞癌的 5 年生存率为 24.7%(95%CI:12.8%-38.7%),而 ACC 为 90.5%(95%CI:73.3%-96.8%)(P<0.001)。
原发性气管肿瘤非常罕见;鳞状细胞癌是最常见的组织学类型,其次是 ACC。一般 5 年总生存率较差,但与局部或远处疾病相比,局部疾病的生存率较好。鳞状细胞癌和 ACC 之间的生存率存在显著差异。